2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Sunday, November 8, 2015

4:30PM-6:00PM: Abstract Number: 1068

Assessment of 10-Year Risk of Myocardial Infarction or Stroke in SLE

Systemic Lupus Erythematosus - Clinical Aspects and Treatment II: Patient-Reported Measures, Outcomes and Reporting

4:30PM-6:00PM: Abstract Number: 1005

Association of Baseline Knee Sagittal Dynamic Joint Stiffness during Gait and 2-Year Cartilage Damage Progression in Knee Osteoarthritis (OA)

Osteoarthritis - Clinical Aspects I: Imaging and Epidemiology

4:30PM-6:00PM: Abstract Number: 1065

Atherosclerotic Vascular Events in a Multinational SLE Inception Cohort: Description and Predictive Risk Factors over a 15 Year Period

Systemic Lupus Erythematosus - Clinical Aspects and Treatment II: Patient-Reported Measures, Outcomes and Reporting

4:30PM-6:00PM: Abstract Number: 1073

B Cell Subsets Are Epigenetically and Transcriptionally Dysregulated in Systemic Lupus Erythematosus

Systemic Lupus Erythematosus - Human Etiology and Pathogenesis: Genetics, Gene Expression, and Epigenetics

4:30PM-6:00PM: Abstract Number: 1045

Baricitinib, Methotrexate, or Baricitinib Plus Methotrexate in Patients with Early Rheumatoid Arthritis Who Had Received Limited or No Treatment with Disease-Modifying Anti-Rheumatic Drugs (DMARDs): Phase 3 Trial Results

Rheumatoid Arthritis-Small Molecules, Biologics and Gene Therapy II: Small Molecular Targeted Therapies

4:30PM-6:00PM: Abstract Number: 1072

Baseline Gene Expression Profiles in 1760 Patients from Two Phase III Trials of BAFF/BLyS Blockade in SLE

Systemic Lupus Erythematosus - Human Etiology and Pathogenesis: Genetics, Gene Expression, and Epigenetics

4:30PM-6:00PM: Abstract Number: 1019

Brain Functional Connectivity Differentially Predicts Response to Two Centrally Acting Analgesics in Fibromyalgia

Pain: Basic Aspects

4:30PM-6:00PM: Abstract Number: 1070

CD 14(C-159T) Polymorphism and Soluble CD14 Are Associated with Increased Disease Activity and Nephritis in SLE

Systemic Lupus Erythematosus - Human Etiology and Pathogenesis: Genetics, Gene Expression, and Epigenetics

4:30PM-6:00PM: Abstract Number: 1007

Change in Semi-Quantitative Imaging Biomarkers Predicts Knee Osteoarthritis Progression: Data from the Fnih OA Biomarkers Consortium

Osteoarthritis - Clinical Aspects I: Imaging and Epidemiology

4:30PM-6:00PM: Abstract Number: 1090

Characteristics and Trajectories of Child Pain, Function, and Psychological Outcomes Associated with Conversion Disorder in Intensive Interdisciplinary Pediatric Pain Rehabilitation

ACR/ARHP Combined Abstract Session: Rehabilitation

4:30PM-6:00PM: Abstract Number: 1047

Characterization of Changes in Lymphocyte Subsets in Baricitinib-Treated Patients with Rheumatoid Arthritis in Two Phase 3 Studies

Rheumatoid Arthritis-Small Molecules, Biologics and Gene Therapy II: Small Molecular Targeted Therapies

4:30PM-6:00PM: Abstract Number: 1069

Child’s HLA-DRB1 Genotype Increases Maternal Risk of Systemic Lupus Erythematosus: Results from the Mother-Child Immunogenetic Study in Autoimmunity

Systemic Lupus Erythematosus - Human Etiology and Pathogenesis: Genetics, Gene Expression, and Epigenetics

4:30PM-6:00PM: Abstract Number: 1016

Collagen Antibodies Induce Pain-like Behavior in Mice Independent of Inflammation and Complement Activation but Requires FcÎ³rs

Pain: Basic Aspects

4:30PM-6:00PM: Abstract Number: 1015

Contribution of TNF and Type I Interferon to the Development of Persistent Post-Inflammatory Mechanical Allodynia in Arthritic Mice

Pain: Basic Aspects

4:30PM-6:00PM: Abstract Number: 1078

CXCL4 Does Not Predict Extent or Progression of Interstitial Lung Disease in Systemic Sclerosis

Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's - Clinical Aspects and Therapeutics I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].